118例多囊卵巢综合征患者的临床诊治分析(1)
 |
| 第1页 |
参见附件(2320KB，2页)。
【摘要】 目的：探讨并比较二甲双胍、罗格列酮治疗多囊卵巢综合征的临床诊治疗效。方法：将我院2008年2月～2009年12月收治的118例高胰岛素血症的多囊卵巢综合征患者随机分为两组各59例，其中观察组给予二甲双胍治疗，对照组采用罗格列酮治疗，观察并比较两组空腹血胰岛素水平、睾酮、黄体生成素、促卵泡激素变化情况。结果：两组治疗后空腹血胰岛素水平、睾酮、黄体生成素均较治疗前有明显改善(P<0.05)，促卵泡激素水平下降不显著(P>0.05)。二甲双胍治疗组治疗后空腹血胰岛素水平、睾酮、黄体生成素水平与罗格列酮治疗组治疗后水平比较有统计学差异(P<0.05)。两组不良反应发生率比较有统计学差异(x2=5.19，P<0.05)。结论：临床治疗多囊卵巢综合征伴高胰岛素血症患者采用二甲双胍治疗更为理想。
【关键词】 多囊卵巢综合征；二甲双胍；罗格列酮
118 patients with polycystic ovary syndrome Clinical analysis of patients
CHEN Aimin
(Xinghua City Second People's Hospital 225700)
【Abstract】Objective: To evaluate and compare metformin, rosiglitazone treatment polycystic ovarian syndrome patients. Methods: The hospital in February 2008 ~ December 2009 118 patients admitted to hyperinsulinemia in polycystic ovary syndrome were randomly divided into two groups of the 59 cases, including the observation group given metformin, the control group were Roger rosiglitazone treatment groups were observed and compared the level of fasting blood insulin, testosterone, luteinizing hormone, follicle stimulating hormone changes. Results: After treatment, fasting blood insulin, testosterone, luteinizing hormone significantly improved compared with before treatment (P <0.05), decreased follicle-stimulating hormone levels were not significant (P> 0.05). After metformin treatment, fasting blood insulin, testosterone, luteinizing hormone levels and rosiglitazone treatment group, compared the level of statistical significance (P <0.05). The incidence of adverse reactions compared the two groups were significantly different (x2 = 5.19, P <0.05). Conclusion: The clinical treatment of PCOS patients with hyperinsulinemia by metformin treatment is more ideal.
【Key words】polycystic ovary syndrome; metformin; rosiglitazone
多囊卵巢综合征近年来发病率有所上升，占育龄期妇女的6%~8%，且多数存在胰岛素抵抗[1]。我院于2008年2月~2009年12月对收治的59例伴高胰岛素血症的多囊卵巢综合征患者给予二甲双胍治疗，并与同期收治的采用罗格列酮治疗的59例患者进行对照研究。现将研究结果报道如下。
1资料与方法
1.1一般资料
选取我院2008年2月~2009年12月收治的118例伴高胰岛素血症的多囊卵巢综合征患者为本次研究对象。118例患者年龄22~38岁，平均(28.3±2.1)岁；其中未婚者26例，已婚者92例；初潮年龄为12岁~14岁。其中有闭经者32例，月经量少者86例。所有患者入组前3个月内均无激素类药物应用史，入组前6个月未发生妊娠、流产、分娩，且未服用影响脂类代谢药物。将118例随机分为两组即观察组、对照组各59例，两组在年龄、婚育史及初潮年龄等资料上无统计学差异(P>0.05)。
1.2诊断标准[2] ......
您现在查看是摘要介绍页，详见PDF附件(2320KB，2页)。